Resources for Parkinson’s Disease Drug Discovery

Charles River has developed extensive experience in identifying and validating novel PD therapeutics from early stage target identification to developing an IND-ready data package. Some of the portfolio highlights include high-content imaging-based assays to measure PD-specific readouts including alpha-synuclein aggregation and changes in mitophagy. Additionally, we offer a comprehensive and translatable modeling platform of chemically and biologically induced models as well as genetic models to study mechanism of action and efficacy of novel PD therapies.


Parkinson’s Disease Resources